Last updated on September 2018

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

Brief description of study

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase. Once RP2D is determined from either the intradermal or subcutaneous group, an additional 40 patients evaluable for response may be enrolled as an expansion cohort at this dose and route of administration to confirm safety and tolerability. Separate from the dose-ascending cohort and RP2D expansion cohort described previously, and once the intradermal dose-ascending cohort is completed, up to 20 MDS patients who are refractory to treatment with hypomethylating agents (HMAs) will be enrolled into an MDS expansion cohort. Of these 20 MDS patients, one-half will receive DSP-7888 at 10.5 mg according to the modified schedule employed in Phase 1 (every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks; [MDS Cohort 1]). The other half of the MDS patients will receive DSP-7888 at 10.5 mg in an alternative dosing schedule where DSP-7888 is administered every 2 weeks until Week 24, after which it will be administered every 4 weeks (MDS Cohort 2).

Clinical Study Identifier: NCT02498665

Contact Investigators or Research Sites near you

Start Over

Emory University Winship Cancer Institute

Atlanta, GA United States

USOR - TX Oncology Austin

Austin, TX United States

USOR -TX Oncology Dallas

Dallas, TX United States

USOR - TX Oncology Tyler

Tyler, TX United States

USOR - VA Cancer Specialists

Fairfax, VA United States

USOR - VA Oncology Associates

Norfolk, VA United States

USOR - Rocky Mountain Cancer Center

Denver, CO United States

Horizon Oncology Research

Lafayette, IN United States

Gabrail Cancer Center Research

Canton, OH United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.